These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38237075)

  • 1. von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease.
    Sidonio RF; Boban A; Dubey L; Inati A; Kiss C; Boda Z; Lissitchkov T; Nemes L; Novik D; Peteva E; Taher AT; Timofeeva MA; Vilchevska KV; Vdovin V; Werner S; Knaub S; Djambas Khayat C
    Blood Adv; 2024 Mar; 8(6):1405-1414. PubMed ID: 38237075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.
    Nowak-Göttl U; Krümpel A; Russo A; Jansen M
    Haemophilia; 2013 Nov; 19(6):887-92. PubMed ID: 23919249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
    Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
    Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a VWF/FVIII concentrate (wilate
    Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
    Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
    Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease.
    Sholzberg M; Khair K; Yaish H; Rodgers G; Cruz MS; Mejía CM; Čermáková Z; Matino D; Teitel J; Barrie A; Werner S; Prondzinski MVD
    TH Open; 2021 Jul; 5(3):e264-e272. PubMed ID: 34235395
    [No Abstract]   [Full Text] [Related]  

  • 10. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience.
    Khair K; Batty P; Riat R; Bowles L; Burgess C; Chen YH; Hart D; Platton S; Pasi J; Liesner R
    Haemophilia; 2015 Jan; 21(1):e44-50. PubMed ID: 25112927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
    J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin
    Gouider E; Klukowska A; Maes P; Platokouki H; Pujol S; Henriet C; Bridey F; Goudemand J
    Blood Transfus; 2023 Jan; 21(1):83-92. PubMed ID: 35543677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.
    Goudemand J; Bridey F; Claeyssens S; Itzhar-Baïkian N; Harroche A; Desprez D; Négrier C; Chamouni P; Chambost H; Henriet C; Susen S; Borel-Derlon A
    J Thromb Haemost; 2020 Aug; 18(8):1922-1933. PubMed ID: 32445594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study.
    Halimeh S; Krümpel A; Rott H; Bogdanova N; Budde U; Manner D; Faeser B; Mesters R; Nowak-Göttl U
    Thromb Haemost; 2011 Apr; 105(4):597-604. PubMed ID: 21301780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
    Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
    Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.